Latest Breaking News On - Epicentrx inc - Page 8 : comparemela.com

EpicentRx Publishes Proof-of-Concept Research on AdAPT-001

/PRNewswire/ EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer.

United statesTonyr reidEpicentrx incAmerican journal of cancer researchAmerican journalCancer researchChief executive officer

EpicentRx Granted New Composition of Matter Patent for Its TGF-ß Trap Fusion Protein

/PRNewswire/ EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer.

United statesTonyr reidTrademark officePrnewswire epicentrx incEpicentrx incUnited states patentFusion proteinsTrap fusion proteinChief executive officer

EpicentRx Announces Completion of First Cohort in Phase 1 BETA PRIME Trial with AdAPT-001

EpicentRx Announces Completion of First Cohort in Phase 1 BETA PRIME Trial with AdAPT-001
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesChristopher larsonTonyr reidTony reidEpicentrx incViral therapyChief executive officerHuman studySubjects with refractory solid tumors

EpicentRx, Inc in an Expansive Growth Phase

Share this article Share this article LA JOLLA, Calif., Jan. 6, 2021 /PRNewswire/ EpicentRx, a clinical stage immuno-oncology company pioneering adaptable oncolytic adenovirus therapeutics as well as a small molecule CD47 antagonist called RRx-001 to address unmet needs in cancer, today announced $10 million in growth capital financing from Silicon Valley Bank (SVB) to bolster both programs. These growth capital funds will be used to accelerate the company s AdAPT platform, built on EpicentRx s next-generation adenovirus viral vector technology, to advance the program s lead clinical stage product, AdAPT-001, a phase 1 oncolytic adenovirus vector, with proprietary TGF-beta targeting modifications for enhanced anti-cancer immune activation. EpicentRx will also further support its novel small molecule RRx-001, currently advancing in a phase 3 global trial with SciClone Pharmaceuticals as part of a partnership established in 2020.

Prnewswire epicentrxFranck brinkhausIgor dacruzSilicon valley bankSciclone pharmaceuticalsEpicentrx incPublic relations officeLife scienceSilicon valleyசிலிக்கான் பள்ளத்தாக்கு வங்கிபொது உறவுகள் அலுவலகம்வாழ்க்கை அறிவியல்சிலிக்கான் பள்ளத்தாக்கு